Monday, 31 July 2023

#RapeseedOil Inhibits The Clusters of Metabolic Syndrome Associated with CardiovascularDisease and Non Fatty #LiverDiseases

Kyle J. Norton

Metabolic syndrome is a cluster of conditions associated with the increased risk of cardiovascular disease and diabetes.

The health problems found in the group include too much fat around the waist, elevated blood pressure, high triglycerides, elevated blood sugar, and low HDL cholesterol.

In other words, if you have 3 of the conditions in the group, your risk of CVD and diabetes are increased substantially compared to those who have less.

According to the statistics, approximately 30% of people in the US are living with metabolic syndrome.

Believe it or not, among US adults aged 18 years or older, the prevalence of metabolic syndrome rose by more than 35% from 1988–1994 to 2007–2012, increasing from 25.3% to 34.2%.

Rapeseed, also known as rape, or oilseed rape, is a member of the family Brassicaceae (mustard or cabbage family), cultivated in suitable climate regions for its oil-rich seed for commercial profits.

To find a potential compound for the prevention of heart disease, researchers at the University of Applied Sciences investigated the effects of a hypo energetic diet with low energy density (ED) enriched in rapeseed oil-derived n-3 fatty acid α-linolenic acid (ALA), in patients with metabolic syndrome.

The human trial included eighty-one patients with metabolic syndrome randomly assigned to receive either rapeseed oil derived with high MUFA content and an ALA intake of 3.5 g/d on body weight or olive oil diet rich in MUFA but with a low ALA content.

According to the results, after a 6-month dietary intervention, the rapeseed oil and olive oil groups showed a significant in reduced body weight and metabolic factors associated with cardiovascular risk.

In other words, intervention groups with rapeseed oil not only significantly decrease the systolic blood pressure, but also reduce total cholesterol and LDL-cholesterol, and insulin levels in patients with metabolic syndrome.

More interestingly, serum triglycerides (TAG) associated with cardiovascular and nonfatty liver disease risk factors were significantly reduced only in the high ALA intake, compared to no effect on the low ALA group.

Based on the findings, researchers said, "Our dietary food pattern with a low ED and high intakes of MUFA and ALA may be a practical approach for long-term dietary treatment in patients with the metabolic syndrome".

Taken altogether, rapeseed oil may be considered a supplement for the prevention and treatment of metabolic syndrome, pending the confirmation of the larger sample size and multicenter human study.


Natural Medicine for Fatty Liver And Obesity Reversal - The Revolutionary Findings To Achieve Optimal Health And Lose Weight

How To Get Rid Of Eye Floaters
Contrary To Professional Prediction, Floaters Can Be Cured Naturally

Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months


Back to Kyle J. Norton's Homepage http://kylejnorton.blogspot.ca


Author Biography
Kyle J. Norton (Scholar, Master of Nutrition, All right reserved)
Health article writer and researcher; Over 10.000 articles and research papers have been written and published online, including worldwide health, ezine articles, article base, health blogs, self-growth, best before it's news, the Karate GB Daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as the international journal Pharma and Bioscience, ISSN 0975-6299.

Sources
(1) Effects of a rapeseed oil-enriched hypo energetic diet with a high content of α-linolenic acid on body weight and cardiovascular risk profile in patients with the metabolic syndrome by Baxheinrich A1, Stratmann B, Lee-Barkey YH, Tschoepe D, Wahrburg U. (PubMed)

No comments:

Post a Comment